文献速递消化系统肿瘤

KRAS与BRAFV600E突变在原发性结直肠癌中的预后影响依赖于CMS分型

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究基于挪威1197例I-IV期结直肠癌及GSE39582数据集514例患者,分析KRAS与BRAFV600E突变在CMS亚型中的预后价值。结果显示BRAFV600E突变在CMS1型MSS肿瘤中富集并与转移及不良预后相关(HR 7.73),KRAS突变的不良预后局限于CMS2/CMS3型MSS肿瘤(HR 1.51)。

要点

  • BRAFV600E突变在CMS1型MSS结直肠癌中富集且与转移和不良总生存相关。
  • KRAS突变的不良预后仅见于CMS2/CMS3型MSS结直肠癌。
  • CMS分型可细化KRAS/BRAFV600E突变在MSS结直肠癌中的预后分层。

核心结论

  • BRAFV600E突变在CMS1型MSS肿瘤中富集并与转移性疾病相关,导致该亚型预后不良。
  • KRAS突变在上皮样(CMS2/CMS3)MSS肿瘤中与不良结局相关。

研究设计与样本

  • 研究纳入挪威队列1197例I-IV期原发性结直肠癌肿瘤,分析MSI及KRAS(密码子12、13、61)和BRAF(密码子600)热点突变状态。
  • 对其中317例样本进行基因表达分析并获得可信的CMS分类,该队列扩展了公共数据集GSE39582中514例患者的临床和分子数据(含CMS分类)。

主要发现

  • BRAFV600E和KRAS突变均仅在MSS肿瘤中与较差的5年总生存相关(BRAFV600E突变 vs KRAS/BRAF野生型:HR 2.85,P < 0.001;KRAS突变 vs KRAS/BRAF野生型:HR 1.30,P = 0.013)。
  • BRAFV600E突变的MSS肿瘤在CMS1中强烈富集并与转移性疾病相关,导致该亚型预后不良(OS:BRAFV600E突变 vs 野生型:HR 7.73,P = 0.001)。
  • KRAS突变的不良预后仅限于具有CMS2/CMS3上皮样基因表达谱的MSS肿瘤(OS:KRAS突变 vs 野生型:HR 1.51,P = 0.011)。
  • BRAFV600E和KRAS突变对基因表达特征的影响因MSI状态和CMS分组而异,佐证了亚型特异性预后关联。

临床怎么用

  • 在MSS结直肠癌中,可结合CMS分型评估BRAFV600E和KRAS突变的预后意义。
  • CMS1型MSS肿瘤伴BRAFV600E突变提示预后极差,需加强监测或考虑强化治疗。
  • CMS2/CMS3型MSS肿瘤伴KRAS突变提示不良结局,可作为风险分层参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer (CRC) varies with microsatellite instability (MSI) status. The gene expression-based consensus molecular subtypes (CMSs) of CRC define molecularly and clinically distinct subgroups, and represent a novel stratification framework in biomarker analysis. We investigated the prognostic value of these mutations within the CMS groups. PATIENTS AND METHODS: Totally 1197 primary tumors from a Norwegian series of CRC stage I-IV were analyzed for MSI and mutation status in hotspots in KRAS (codons 12, 13 and 61) and BRAF (codon 600). A subset was analyzed for gene expression and confident CMS classification was obtained for 317 samples. This cohort was expanded with clinical and molecular data, including CMS classification, from 514 patients in the publically available dataset GSE39582. Gene expression signatures associated with KRAS and BRAFV600E mutations were used to evaluate differential impact of mutations on gene expression among the CMS groups. RESULTS: BRAFV600E and KRAS mutations were both associated with inferior 5-year overall survival (OS) exclusively in MSS tumors (BRAFV600E mutation versus KRAS/BRAF wild-type: Hazard ratio (HR) 2.85, P < 0.001; KRAS mutation versus KRAS/BRAF wild-type: HR 1.30, P = 0.013). BRAFV600E-mutated MSS tumors were strongly enriched and associated with metastatic disease in CMS1, leading to negative prognostic impact in this subtype (OS: BRAFV600E mutation versus wild-type: HR 7.73, P = 0.001). In contrast, the poor prognosis of KRAS mutations was limited to MSS tumors with CMS2/CMS3 epithelial-like gene expression profiles (OS: KRAS mutation versus wild-type: HR 1.51, P = 0.011). The subtype-specific prognostic associations were substantiated by differential effects of BRAFV600E and KRAS mutations on gene expression signatures according to the MSI status and CMS group. CONCLUSIONS: BRAFV600E mutations are enriched and associated with metastatic disease in CMS1 MSS tumors, leading to poor prognosis in this subtype. KRAS mutations are associated with adverse outcome in epithelial (CMS2/CMS3) MSS tumors.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Smeby J, Sveen A, Merok MA, et al. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol. 2018. PMID: 29518181. doi:10.1093/annonc/mdy085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。